Pharmacokinetic/Pharmacodynamic Analysis the Probability of Target Attainment of Posaconazole against Mucorales Species in Patients with Mucormycosis
Open Access
- 1 January 2020
- journal article
- research article
- Published by Scientific Research Publishing, Inc. in Pharmacology & Pharmacy
- Vol. 11 (05), 71-78
- https://doi.org/10.4236/pp.2020.115007
Abstract
The objective of this study was to investigate the probability of target attainment of various posaconazole dosing regimens against Mucorales species in patients with mucormycosis. According to pharmacokinetic/pharmacodynamic parameters of posaconazole in adults, the dosage regimen of posaconazole for mucormycosis included 50, 100, 200 and 400 mg orally q12h. Monte Carlo Simulation analysed the published parameters of pharmacokinetics and the MIC values of mucormycosis in Mucorales species. The results showed that posaconazole did not affect Rhizopus arrhizus and Mucor sp. The optimal dosage of posaconazole for Rhizopus microsporus and Rhizomucor pusillus was 400 mg orally q12h and the best dosage regimen for Lichtheimia corymbifera was 200 mg orally q12h. The antifungal activity of posaconazole against mucormycosis was different, and the dosage regimen needs to adjust according to fungal species.Keywords
This publication has 16 references indexed in Scilit:
- Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic AnalysisAntimicrobial Agents and Chemotherapy, 2014
- Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and MucormycosisAntimicrobial Agents and Chemotherapy, 2014
- Combat-Related Invasive Fungal Wound InfectionsCurrent Fungal Infection Reports, 2014
- Analysis of a Food-Borne Fungal Pathogen Outbreak: Virulence and Genome of a Mucor circinelloides Isolate from YogurtmBio, 2014
- ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013Clinical Microbiology & Infection, 2014
- DNA barcoding in Mucorales: an inventory of biodiversityPersoonia - Molecular Phylogeny and Evolution of Fungi, 2013
- Mucormycosis treated with posaconazole: review of 96 case reportsCritical Reviews in Microbiology, 2012
- Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007Clinical Microbiology & Infection, 2011
- Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14α-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole BindingAntimicrobial Agents and Chemotherapy, 2004
- Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy AdultsAntimicrobial Agents and Chemotherapy, 2003